Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants, announced on April 11, 2025, include an aggregate of 96,800 options with an exercise price of $2.72 per share, matching the closing price on April 7, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters, contingent on continued employment.

Positive

• Employee retention strategy implemented through long-term stock options
• Alignment of employee interests with shareholders through equity compensation

Negative

• Potential future dilution of existing shareholders from 96,800 new stock options

CAMBRIDGE, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).

Fulcrum granted the new employees an aggregate of 96,800 options to purchase shares of the company’s common stock at an exercise price of $2.72 per share, the closing price per share of Fulcrum’s common stock as reported on the grant effective date, April 7, 2025. Each option has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and an additional 6.25% of the shares vesting in equal quarterly installments over the twelve successive quarters following the first anniversary, subject to the applicable employee’s continued service with the company through the applicable vesting dates.

About Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:

Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856

FAQ

What is the exercise price for FULC's newly granted stock options in April 2025?

The exercise price is $2.72 per share, which was Fulcrum's closing stock price on April 7, 2025.

How many stock options did Fulcrum Therapeutics (FULC) grant to new employees in April 2025?

Fulcrum granted an aggregate of 96,800 stock options to two new employees.

What is the vesting schedule for FULC's April 2025 employee stock options?

25% vests after one year, followed by 6.25% quarterly over the next twelve quarters, requiring continued employment.

How long is the term of FULC's April 2025 employee stock options?

The options have a ten-year term.